Skip to content
StackItSmart
BHuman cohort / observational
CardiotoxicHigh risk

Toremifene

Fareston

Toremifene (brand name Fareston) is an oral selective estrogen receptor modulator (SERM), a chlorinated analog of tamoxifen, approved for estrogen-receptor-positive metastatic breast cancer. Like other SERMs it blocks estrogen at some tissues (breast) while acting estrogen-like at others (bone, liver, and the cardiac ion channels), so in men it raises LH/FSH and testosterone by blocking estrogen negative feedback at the hypothalamus/pituitary, which is why it is used off-label in the enhanced-athletics community for estrogen management, gynecomastia, and HPTA recovery. The single most serious documented danger is dose-dependent QT-interval prolongation, which can trigger torsade de pointes (a potentially fatal arrhythmia); the drug's own label carries a boxed warning for this. It also raises venous thromboembolism (blood clot) risk and can cause fatty liver and liver-enzyme elevation. Because it manipulates the hormonal axis, it should never be used as a substitute for endocrinologist-directed care. Nearly all high-quality human trial data come from breast-cancer patients and from men on androgen-deprivation therapy for prostate cancer; there are essentially no randomized trials of toremifene for post-cycle recovery in men who have used anabolic steroids, so that specific use is an extrapolation, not an evidence-based protocol. The overall evidence grade below reflects RCT-level data for the approved oncology/ADT-bone/lipid indications; it does not extend to the off-label HPTA-recovery use, which remains unsupported by controlled trials.

Clinical readoutAncillary · serm
Hepatic strainModerate
CardiovascularModerate
HPTA suppressionNone
Half-life
5 d
Route
Oral
Evidence
B
Active
Long-acting: with a ~5-…
5 d10 d15 d20 d3.6 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Approximately 5 days for the parent drug (terminal elimination), reflecting extensive protein binding and enterohepatic recirculation; the principal metabolite N-desmethyltoremifene has a longer half-life (~6 days).
Pharmacology

Mechanism of action

Toremifene is a triphenylethylene SERM that binds the estrogen receptor and acts as a tissue-selective agonist/antagonist. It antagonizes estrogen in breast tissue (its approved anticancer action) but behaves as a partial estrogen agonist in bone (preserving/increasing bone mineral density) and in the liver (improving the lipid profile). At the hypothalamic-pituitary level it blocks estrogen-mediated negative feedback, increasing GnRH-driven secretion of LH and FSH, which in men raises endogenous testosterone, SHBG, and inhibin B. Its estrogen-agonist-like action on cardiac repolarization (an estradiol-like effect on ion channels/hERG) is thought to underlie its propensity to prolong the QT interval.
Kinetics

Pharmacokinetics

Half-life

Approximately 5 days for the parent drug (terminal elimination), reflecting extensive protein binding and enterohepatic recirculation; the principal metabolite N-desmethyltoremifene has a longer half-life (~6 days).

Active duration

Long-acting: with a ~5-day half-life, steady state is not reached until roughly 4–6 weeks of daily dosing, and after stopping, washout takes several weeks. This long tail matters for monitoring and for clinician discussion of drug interactions and pre-procedure planning; it is not information for evading any testing.

Route

Oral; bioavailability is high (estimated near 100%). Reported human doses: 60 mg/day (breast cancer, male fertility studies) and 80 mg/day (prostate-cancer bone trials), stated only to attach each risk to its studied dose, not as a recommendation.

Metabolism & clearance

Extensively metabolized in the liver by cytochrome P450 (chiefly CYP3A4) to N-desmethyltoremifene and other metabolites, some retaining biologic activity. Eliminated primarily in the feces following enterohepatic circulation; renal excretion is minor. Hepatic impairment prolongs exposure, whereas age and renal function have little effect.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Increases bone mineral density at the lumbar spine, hip, and femoral neck and reduces bone-turnover markers in men on androgen-deprivation therapy (human RCT).
  • Reduced incidence of new vertebral (morphometric) fractures over 2 years in men on androgen-deprivation therapy (human RCT).
  • Improves the fasting lipid profile: lowers total cholesterol, LDL cholesterol, and triglycerides and raises HDL cholesterol (human RCT).
  • Raises FSH, testosterone, SHBG, and inhibin B and improves sperm count, motility, and morphology in men with idiopathic oligozoospermia (uncontrolled human clinical trial).
  • Antagonizes estrogen in breast tissue (approved use in ER-positive breast cancer).
  • Common estrogen-antagonist class effects reported in trials include hot flashes/vasomotor symptoms.
Safety

Adverse effects by system

Cardiovascular

Most serious: dose-dependent QT-interval prolongation with potential for torsade de pointes and other ventricular arrhythmias. The SERM class (tamoxifen, toremifene) shows a disproportionately higher reporting rate of long QT, torsade, and ventricular arrhythmia versus aromatase inhibitors in pharmacovigilance data, with high mortality among those who develop ventricular arrhythmia. Toremifene also increases venous thromboembolism risk (see hematologic). Lipid parameters improve, but the electrophysiologic and thrombotic risks are the dominant cardiovascular concerns.

Hepatic

Associated with non-alcoholic fatty liver disease and alanine aminotransferase (ALT) elevation in a retrospective cohort of SERM-treated patients; changes were generally reversible after discontinuation with no progression to cirrhosis in that cohort. Hepatic impairment prolongs drug exposure.

Endocrine / HPTA

As a SERM it raises LH, FSH, testosterone, SHBG, and inhibin B by blocking estrogen negative feedback (documented in men with oligozoospermia). This is the intended off-label 'recovery/anti-estrogen' effect but also means it actively perturbs the hormonal axis; hot flashes/vasomotor symptoms are common estrogen-antagonist effects.

Reproductive

In men it increases gonadotropins and testosterone and improves semen parameters (SERM effect on the reproductive axis). In women it is an estrogen antagonist in breast tissue; secondary endometrial cancer incidence appears lower than with tamoxifen and similar to raloxifene, and it may unmask rather than induce endometrial tumors.

Neuropsychiatric

No well-characterized primary human data specific to toremifene establish a distinct psychiatric adverse-effect profile; mood changes are not a prominently reported signal. Data are inadequate to characterize this system.

Renal

No clinically significant renal toxicity is described in the human literature, and renal function does not meaningfully alter its pharmacokinetics. No adequate data suggest a direct nephrotoxic effect.

Hematologic

Increased venous thromboembolic events versus placebo in the phase III prostate-cancer trial (2.6% toremifene vs 1.1% placebo over 2 years). SERM-class thrombotic risk (deep vein thrombosis, pulmonary embolism) is the key hematologic concern, though comparative reviews suggest the magnitude may be somewhat lower than tamoxifen or raloxifene.

Dermatologic

Vasomotor symptoms (hot flashes, sweating) are reported; no distinct serious dermatologic toxicity is well characterized for toremifene specifically in the primary literature reviewed.

Recovery

HPTA suppression & recovery

Suppression: Toremifene does not suppress the HPTA; as a SERM it stimulates it — raising LH, FSH, and testosterone by blocking estrogen negative feedback.

Because it increases gonadotropins and testosterone (documented in men with oligozoospermia, PMID 17412336), toremifene is used off-label as a single-SERM approach to support HPTA recovery, but there are no randomized controlled trials of this use in men recovering from anabolic-androgenic steroids, so any such use is an extrapolation, not evidence-based. Recovery of the axis is highly variable and individual. This monograph describes single-SERM framing only and does not endorse dual-SERM protocols. Any recovery attempt should be directed and monitored by an endocrinologist, who can interpret LH/FSH/testosterone/estradiol trends and weigh the QT and thrombotic risks.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and follow-up ECG for QTc interval (given the boxed QT warning)Serum electrolytes, especially potassium and magnesium, corrected before and during useLiver function tests (ALT/AST) at baseline and periodicallyFasting lipid panelIn men using it for hormonal reasons: LH, FSH, total and free testosterone, estradiol, and SHBG, interpreted by a clinicianConsider bone mineral density (DEXA) where bone health is the indication

Cadence: Baseline before starting; ECG and electrolytes early after initiation and after any dose change or added interacting drug; liver enzymes, lipids, and hormone panel periodically (e.g., every ~3 months) while on the drug and after stopping, under clinician direction. Because of the ~5-day half-life, effects and levels persist for weeks after the last dose.

Warning signs — seek care
  • Palpitations, fainting or near-fainting, dizziness, or seizure (possible arrhythmia/torsade) — seek emergency care
  • Leg swelling, pain, or warmth; sudden shortness of breath, chest pain, or coughing blood (possible DVT/pulmonary embolism) — seek emergency care
  • Yellowing of skin/eyes, dark urine, right-upper-abdominal pain, or marked fatigue (possible liver injury)
  • Any new fainting spells or known family history of sudden cardiac death should prompt immediate discontinuation and medical review
Do not use if

Contraindications

  • Congenital or acquired long QT syndrome, or a personal/family history of QT prolongation.
  • Uncorrected hypokalemia or hypomagnesemia (these potentiate QT prolongation and torsade).
  • Concurrent use of other QT-prolonging drugs or strong CYP3A4 inhibitors (raise toremifene levels).
  • History of venous thromboembolism (deep vein thrombosis, pulmonary embolism) or other thromboembolic disorders.
  • Significant hepatic impairment (reduced clearance, higher exposure).
  • Pregnancy and women who may become pregnant (estrogen-receptor–active agent); not appropriate for anyone who cannot be monitored for cardiac and thrombotic risk.
Combinations

Interaction profile

  • MajorWith another SERM: Blood / clotting
  • ModerateWith an aromatase inhibitor: Hormonal
  • MajorWith a thermogenic stimulant: QT prolongation
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is educational information, not medical advice, and does not create a doctor-patient relationship; toremifene carries serious cardiac and clotting risks and should only be used under a physician's supervision with regular bloodwork. 21+ only.
  • The dominant danger is QT prolongation and torsade de pointes: get a baseline ECG and correct low potassium/magnesium before use, and avoid combining with other QT-prolonging drugs or strong CYP3A4 inhibitors. Fainting, palpitations, or seizures are a medical emergency — stop and seek care immediately.
  • Stop the drug and seek urgent care for signs of a blood clot: leg swelling/pain, sudden breathlessness, chest pain, or coughing up blood.
  • Get liver enzymes checked periodically; new jaundice, dark urine, or right-upper-abdominal pain warrants stopping and medical evaluation.
  • Because the half-life is ~5 days, the drug and its effects persist for weeks after the last dose — factor this into any monitoring and clinician conversation.
  • There are no randomized trials supporting toremifene for post-anabolic-steroid HPTA recovery; do not treat off-label 'recovery' use as validated. Any hormonal-recovery attempt should be directed by an endocrinologist using LH/FSH/testosterone/estradiol labs, and this monograph describes single-SERM framing only.
  • Do not use to self-treat gynecomastia or manipulate hormones without evaluation — an unexamined breast lump or an underlying cardiac or clotting risk can be dangerous to mask.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Toremifene is an oral SERM with ~100% bioavailability, >95% protein binding, hepatic CYP450 metabolism, primarily fecal elimination via enterohepatic circulation, a half-life of ~5 days, steady state by ~6 weeks, with hepatic (not renal or age) factors altering pharmacokinetics.

    ReviewPMID 11108432 ↗

  2. 02

    In a double-blind placebo-controlled phase III RCT, toremifene 80 mg/day in men on androgen-deprivation therapy reduced 2-year new vertebral fractures (2.5% vs 4.9%), increased bone mineral density, and increased venous thromboembolic events (2.6% vs 1.1%).

    RCTPMID 23234631 ↗

  3. 03

    Toremifene 80 mg/day increased venous thromboembolic events versus placebo and reduced vertebral fracture incidence in men on androgen-deprivation therapy (phase III RCT).

    RCTPMID 20723926 ↗

  4. 04

    Toremifene 80 mg/day significantly lowered total cholesterol, LDL, and triglycerides and raised HDL versus placebo in men on androgen-deprivation therapy (phase III RCT interim analysis).

    RCTPMID 18398147 ↗

  5. 05

    Toremifene 80 mg/day increased lumbar spine, total hip, and femoral neck bone mineral density versus placebo in men on androgen-deprivation therapy (phase III RCT interim analysis).

    RCTPMID 18001802 ↗

  6. 06

    In men with idiopathic oligozoospermia, toremifene 60 mg/day raised FSH, testosterone, SHBG, and inhibin B and improved sperm concentration, motility, and morphology — demonstrating stimulation of the hypothalamic-pituitary-testicular axis.

    CohortPMID 17412336 ↗

  7. 07

    SERMs including toremifene are associated with disproportionately higher reporting of long QT, torsade de pointes, and ventricular arrhythmias compared with aromatase inhibitors, consistent with an estradiol-like cardiac effect, with 38% mortality among reported ventricular-arrhythmia cases.

    Case seriesPMID 29720397 ↗

  8. 08

    SERM treatment (tamoxifen/toremifene) was associated with increased non-alcoholic fatty liver disease and ALT elevation that largely reversed after discontinuation, with no progression to cirrhosis.

    CohortPMID 27240168 ↗

  9. 09

    Compared with tamoxifen, toremifene shows lower secondary endometrial cancer incidence (similar to raloxifene), possibly lower stroke/pulmonary embolism/cataract risk, and superior lipid effects; it may unmask rather than induce endometrial tumors.

    ReviewPMID 16289904 ↗

  10. 10

    SERMs (raloxifene and toremifene) increase bone mineral density in GnRH-agonist-treated men, whose hypogonadism is a major cause of acquired osteoporosis.

    ReviewPMID 17062721 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice